HSBC Downgrades AstraZeneca on Failed Heart Trial

HSBC has downgraded AstraZeneca (AZN) to a 'hold' rating from 'buy,' citing a recent phase III trial failure as a significant blow to its growth prospects. The bank also reduced its price target for the pharmaceutical company, indicating a less optimistic outlook.

The failure of the Wainua trial, which focused on a form of heart disease, has removed a critical component of AstraZeneca's investment case, according to HSBC. The outcome was reportedly worse than anticipated by both the bank and AstraZeneca's management.

This development marks a shift in strategy for AstraZeneca, as future revenue growth now depends on more volatile catalysts, with significant readouts anticipated in 2027. Additionally, concerns have been raised regarding two oncology trials scheduled for the second half of 2026, which are considered high-risk.

HSBC warned that a series of trial setbacks could undermine confidence in AstraZeneca's research capabilities, potentially limiting its stock's valuation. The bank has removed Wainua from its financial forecasts, slightly adjusting revenue growth estimates. HSBC now anticipates earnings below the consensus forecast for the current year.

The risk-reward balance for AstraZeneca is no longer deemed attractive by HSBC, with remaining catalysts perceived as having a downward bias. While potential upside exists from positive oncology data and a recovery in its heart and kidney portfolio, the overall outlook has become more challenging. AstraZeneca was a past client of HSBC for securities services.